Roche - NewLink Genetic's cancer immunotherapy....

Options

http://investors.linkp.com/releasedetail.cfm?ReleaseID=876909

Roche will support development of NewLink Genetics' cancer immunotherapy NLG919 to the tune of up to $1 billion, the company said. NewLink previously made headlines for its experimental Ebola vaccine.

Categories